Research News

OCRA Funded Research Delves Deeper into How PARPi Work

(December 21, 2018) This month, researchers in Boston published their findings on how PARP inhibitors (PARPi) cause a chain reaction of responses from the tumor and its environment…

Read on

FDA Approves Olaparib for Frontline Maintenance Treatment in Ovarian Cancer

(December 20, 2018) Earlier this year a phase III clinical trial, known as SOLO-1, showed that frontline olaparib (Lynparza) can reduce the risk of disease progression or death by up to 70% in women with BRCA 1 or 2 positive, advanced stage…

Read on

Neoadjuvant Chemotherapy Recommended for Stage IV Tubo-Ovarian Cancer

(December 7, 2018) A study published last month analyzed two clinical trials that sought to determine the best first step for advanced tubo-ovarian cancers, neoadjuvant chemotherapy or debulking surgery…

Read on

Simple Cysts Found by Ultrasound Don’t Require Action

(November 16, 2018) JAMA Internal Medicine recently published an eleven year study of over 72,000 women that found having a simple ovarian cyst does not increase one’s risk of ovarian cancer…

Read on

For Some, Statin Use Can Decrease the Risk of Ovarian Cancer

(November 13, 2018) The International Journal of Cancer recently published a study that explored the use of statins, which reduces one’s lipids, and their effect on ovarian cancer risk…

Read on

World Ovarian Cancer Coalition Releases Every Woman Study Report

(October 25, 2018) Through a series of surveys, interviews, and literature reviews the World Ovarian Cancer Coalition produced a report that detailed their findings and recommendations…

Read on

Maintenance olaparib Improves Progression-Free Survival in Phase III Clinical Trial

(October 23, 2018) Olaparib, or Lynparza, was shown to increase progression-free survival (PFS) by almost three years in an ongoing trial known as SOLO-1…

Read on

OCRA Research Shows How Cancer Cells Negatively Impact the Communication between the Ovary and Fallopian Tube

(October 22, 2018) A team at the University of Illinois at Chicago, including OCRA grantee Matthew Dean, PhD, recently discovered the role that cancer cells have on their immediate environment. The research was funded in part by OCRA…

Read on

Study Looks at Long-term Survival Trends in Ovarian Cancer

(October 19, 2018) A retroactive study using SEER, or Surveillance, Epidemiology, and End Results, looked at the trends in ovarian cancer from 1983 to 2012. In almost 3 decades, the incidence of ovarian cancer per 100,000 fell from 13.7 to 10…

Read on

Kunle Odunsi, MD, PhD, Elected to National Academy of Medicine

(October 18, 2018) Longtime OCRA Scientific Advisory Committee member and former grantee Kunle Odunsi, MD, PhD, has been elected to the National Academy of Medicine—a distinguished lifetime designation that is considered one of the highest honors…

Read on

OCRA Funded Research Reveals Immune Suppression in Ovarian Cancer

(October 15, 2018) This month in Nature, researchers from Weill Cornell published a study that helps to explain why the body’s natural immune response struggles to fight back against ovarian cancer…

Read on

Certain Kinds of Contemporary Birth Control Pills Shown to Reduce Ovarian Cancer Risk

(October 11, 2018) The BMJ recently published a study from Denmark about the effect that newer birth control pills have on ovarian cancer risk…

Read on